JP7199809B2 - 核酸製品及びその投与方法 - Google Patents
核酸製品及びその投与方法 Download PDFInfo
- Publication number
- JP7199809B2 JP7199809B2 JP2017542098A JP2017542098A JP7199809B2 JP 7199809 B2 JP7199809 B2 JP 7199809B2 JP 2017542098 A JP2017542098 A JP 2017542098A JP 2017542098 A JP2017542098 A JP 2017542098A JP 7199809 B2 JP7199809 B2 JP 7199809B2
- Authority
- JP
- Japan
- Prior art keywords
- rna
- acne
- less
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021163064A JP7638844B2 (ja) | 2015-02-13 | 2021-10-01 | 核酸製品及びその投与方法 |
| JP2024174419A JP2025013347A (ja) | 2015-02-13 | 2024-10-03 | 核酸製品及びその投与方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562116232P | 2015-02-13 | 2015-02-13 | |
| US62/116,232 | 2015-02-13 | ||
| US201562195462P | 2015-07-22 | 2015-07-22 | |
| US62/195,462 | 2015-07-22 | ||
| US201562242383P | 2015-10-16 | 2015-10-16 | |
| US62/242,383 | 2015-10-16 | ||
| US201562245726P | 2015-10-23 | 2015-10-23 | |
| US62/245,726 | 2015-10-23 | ||
| US201662289617P | 2016-02-01 | 2016-02-01 | |
| US62/289,617 | 2016-02-01 | ||
| PCT/US2016/018065 WO2016131052A1 (en) | 2015-02-13 | 2016-02-16 | Nucleic acid products and methods of administration thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163064A Division JP7638844B2 (ja) | 2015-02-13 | 2021-10-01 | 核酸製品及びその投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506542A JP2018506542A (ja) | 2018-03-08 |
| JP2018506542A5 JP2018506542A5 (cg-RX-API-DMAC7.html) | 2019-03-28 |
| JP7199809B2 true JP7199809B2 (ja) | 2023-01-06 |
Family
ID=56615771
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542098A Active JP7199809B2 (ja) | 2015-02-13 | 2016-02-16 | 核酸製品及びその投与方法 |
| JP2021163064A Active JP7638844B2 (ja) | 2015-02-13 | 2021-10-01 | 核酸製品及びその投与方法 |
| JP2024174419A Pending JP2025013347A (ja) | 2015-02-13 | 2024-10-03 | 核酸製品及びその投与方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163064A Active JP7638844B2 (ja) | 2015-02-13 | 2021-10-01 | 核酸製品及びその投与方法 |
| JP2024174419A Pending JP2025013347A (ja) | 2015-02-13 | 2024-10-03 | 核酸製品及びその投与方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11241505B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3256585A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7199809B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109477102A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016218977C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2976376A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016131052A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016070166A2 (en) | 2014-11-02 | 2016-05-06 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| ES2796488T3 (es) * | 2016-04-08 | 2020-11-27 | Krystal Biotech Inc | Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
| WO2018154413A1 (en) * | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
| CN110636854A (zh) * | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
| EP3437650A1 (en) | 2017-07-31 | 2019-02-06 | Accanis Biotech F&E GmbH & Co KG | Treatment of local skin hypotrophy conditions |
| US11707510B2 (en) | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| EP3856914A1 (en) * | 2018-09-26 | 2021-08-04 | Krystal Biotech, Inc. | Compositions and methods for the treatment of skin diseases |
| WO2020146700A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Lipid nanoparticles |
| CN113454105A (zh) | 2019-02-08 | 2021-09-28 | 克里斯托生物技术股份有限公司 | 用于递送cftr多肽的组合物和方法 |
| MA55082A (fr) * | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations Vi Llc | Compositions, procédés, et kits pour l'administration de polyribonucléotides |
| KR102901623B1 (ko) * | 2019-03-01 | 2025-12-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드 및 이의 미용적 용도 |
| WO2020223674A2 (en) * | 2019-05-01 | 2020-11-05 | Board Of Regents Of The University Of Texas System | Methods and compositions for regulating adipogenesis |
| CA3145425A1 (en) * | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP4010481A4 (en) | 2019-08-09 | 2023-09-20 | Nutcracker Therapeutics, Inc. | MICROFLUIDIC DEVICE AND METHODS OF USE |
| EP4149252A4 (en) * | 2020-05-12 | 2024-10-02 | Factor Bioscience Inc. | GENETICALLY ENGINEERED PROTEINS |
| CN114717229B (zh) * | 2021-01-05 | 2024-09-10 | 麦塞拿治疗(香港)有限公司 | 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| IL305958A (en) * | 2021-03-22 | 2023-11-01 | Recode Therapeutics Inc | Polynucleotide preparations, related formulations and methods of using them |
| IL307350A (en) | 2021-04-02 | 2023-11-01 | Krystal Biotech Inc | Viral vectors for cancer treatment |
| EP4334330A1 (en) | 2021-05-07 | 2024-03-13 | Helix Nanotechnologies, Inc. | Modified ribonucleic acids and uses thereof |
| CN114350801B (zh) * | 2022-01-05 | 2023-10-20 | 华北理工大学 | 一种尘肺病人早期筛查的mRNA检测引物组和探针、试剂盒及应用 |
| WO2024229116A2 (en) * | 2023-05-01 | 2024-11-07 | Factor Bioscience Inc. | Methods for reprogramming and gene editing cells |
| CN118496383B (zh) * | 2023-06-02 | 2025-10-31 | 东北农业大学 | 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途 |
| EP4750515A1 (en) * | 2023-07-25 | 2026-06-03 | PassPort Technologies, Inc. | Methods and systems for transdermal immunotherapy |
| CN117783501B (zh) * | 2024-02-26 | 2024-05-10 | 四川大学华西第二医院 | 辛酸钠在注意缺陷与多动障碍中的应用及产品 |
| WO2026114290A1 (zh) * | 2024-11-29 | 2026-06-04 | 仁景(苏州)生物科技有限公司 | 治疗或预防脱发、白发的核酸及其组合物 |
Family Cites Families (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3034507A (en) | 1960-05-10 | 1962-05-15 | American Cyanamid Co | Intracutaneous injection device |
| US3539465A (en) | 1968-10-08 | 1970-11-10 | Ncr Co | Encapsulation of hydrophilic liquid-in-oil emulsions |
| US3675766A (en) | 1970-02-04 | 1972-07-11 | Sol Roy Rosenthal | Multiple puncture injector device |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5849686A (en) | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US6506729B1 (en) | 1991-03-11 | 2003-01-14 | Curis, Inc. | Methods and compositions for the treatment and prevention of Parkinson's disease |
| US5674844A (en) | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6949505B1 (en) | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| ATE493141T1 (de) | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US6602693B1 (en) | 1996-07-03 | 2003-08-05 | Clear Solutions Biotech, Inc. | Gene encoding hyaluronan synthase |
| EP0955999B1 (en) | 1996-08-19 | 2001-12-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Novel liposome complexes for increased systemic delivery |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
| US6316260B1 (en) | 1997-08-22 | 2001-11-13 | Bernina Biosystems Gmbh | Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraether lipid derivatives, and use thereof |
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US7390780B2 (en) | 1999-04-23 | 2008-06-24 | Alza Corporation | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification |
| WO2000074763A2 (en) | 1999-06-04 | 2000-12-14 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| US20110171185A1 (en) | 1999-06-30 | 2011-07-14 | Klimanskaya Irina V | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
| US20020054895A1 (en) | 1999-07-23 | 2002-05-09 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6595947B1 (en) | 2000-05-22 | 2003-07-22 | Becton, Dickinson And Company | Topical delivery of vaccines |
| EP2292632A3 (en) | 2000-09-26 | 2012-07-25 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US7189759B2 (en) | 2001-05-23 | 2007-03-13 | Medicis Pharmaceutical Corporation | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| WO2003018767A2 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| WO2003027277A1 (en) | 2001-09-21 | 2003-04-03 | Japan Science And Technology Corporation | Method of screening reporgramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs |
| US20050053588A1 (en) | 2001-10-18 | 2005-03-10 | Li Yin | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| US20030186249A1 (en) | 2002-04-01 | 2003-10-02 | Zairen Sun | Human TARPP genes and polypeptides |
| JP3785508B2 (ja) | 2002-04-15 | 2006-06-14 | 学校法人慶應義塾 | 遺伝子治療における免疫応答を解析できる実験モデルマウス |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
| JP4579911B2 (ja) | 2003-06-03 | 2010-11-10 | アイシス・ファーマシューティカルズ・インコーポレイテッド | スルビビン発現の調節 |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| BRPI0514641A (pt) | 2004-09-08 | 2008-06-17 | Wisconsin Alumni Res Found | cultivação das células tronco embriÈnica humana |
| BRPI0514778B1 (pt) | 2004-09-08 | 2018-07-10 | Wisconsin Alumni Research Foundation | Meio para cultivar células tronco embrionárias |
| WO2006047728A2 (en) | 2004-10-27 | 2006-05-04 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Bmp gene and fusion protein |
| CA2595695A1 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life |
| CN101203222A (zh) * | 2005-03-30 | 2008-06-18 | 艾升制药公司 | 用于治疗湿疹的丙嗪或紧密相关的化合物 |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| WO2007079886A1 (de) | 2005-12-22 | 2007-07-19 | Csl Behring Gmbh | Oktanoatreduziertes human albumin |
| US7658728B2 (en) | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| GB0623635D0 (en) | 2006-11-27 | 2007-01-03 | Stem Cell Sciences Uk Ltd | Pluripotent cell growth media |
| US7785301B2 (en) | 2006-11-28 | 2010-08-31 | Vadim V Yuzhakov | Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection |
| WO2008073856A2 (en) | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| CN101200758A (zh) | 2006-12-15 | 2008-06-18 | 华中科技大学 | 一种检测col7a1基因突变的方法及其用途 |
| US10829733B2 (en) | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| US20100172882A1 (en) | 2007-01-11 | 2010-07-08 | Glazer Peter M | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| WO2008097926A2 (en) | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| MX348010B (es) | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| KR20100087298A (ko) * | 2007-09-28 | 2010-08-04 | 교와 핫꼬 기린 가부시키가이샤 | 피부 질환의 예방 및/또는 치료제 |
| KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
| BRPI0820762A2 (pt) | 2007-12-14 | 2015-06-16 | Dsm Ip Assests Bv | Processo sol-gel com uma catalisador protegido |
| EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| EP2222696A1 (en) | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| US20110045001A1 (en) | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| JP2011160661A (ja) | 2008-06-02 | 2011-08-25 | Kyowa Hakko Kirin Co Ltd | 血球細胞の初期化法 |
| ES2587395T3 (es) | 2008-06-04 | 2016-10-24 | Cellular Dynamics International, Inc. | Procedimientos para la producción de células IPS usando un enfoque no vírico |
| WO2009147400A1 (en) | 2008-06-05 | 2009-12-10 | Iti Scotland Limited | Stem cell culture media and methods |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP2326711A2 (en) | 2008-08-20 | 2011-06-01 | VIRxSYS Corporation | Compositions and methods for generation of pluripotent stem cells |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP3450545B1 (en) | 2008-10-24 | 2023-08-23 | Wisconsin Alumni Research Foundation | Pluripotent stem cells obtained by non-viral reprogramming |
| KR20160150109A (ko) | 2008-11-18 | 2016-12-28 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 중공 마이크로니들 어레이 |
| EP2881461A1 (en) | 2008-11-21 | 2015-06-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Reprogramming cells toward a pluripotent state |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US20100209404A1 (en) | 2009-02-10 | 2010-08-19 | University Of Dayton | Enhanced method for producing stem-like cells from somatic cells |
| US10894944B2 (en) | 2009-04-10 | 2021-01-19 | Monash University | Cell culture media |
| ES2849181T3 (es) | 2009-04-22 | 2021-08-16 | Viacyte Inc | Composiciones celulares derivadas de células reprogramadas desdiferenciadas |
| US10837020B2 (en) | 2009-04-22 | 2020-11-17 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long RNA molecules |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| EP2251437B1 (en) | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression |
| US8496941B2 (en) | 2009-06-03 | 2013-07-30 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| KR101775926B1 (ko) | 2009-11-04 | 2017-09-07 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 화학 물질을 이용한 에피솜 재프로그래밍 |
| EP2499239A1 (en) | 2009-11-11 | 2012-09-19 | Sanford-Burnham Medical Research Institute | METHOD FOR GENERATION AND REGULATION OF iPS CELLS AND COMPOSITIONS THEREOF |
| ES2769129T3 (es) | 2009-12-07 | 2020-06-24 | Univ Pennsylvania | Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células |
| US20130189741A1 (en) | 2009-12-07 | 2013-07-25 | Cellscript, Inc. | Compositions and methods for reprogramming mammalian cells |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| WO2011094738A1 (en) | 2010-02-01 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced efficiency of induced pluripotent stem cell generation |
| US20140194482A1 (en) | 2010-02-02 | 2014-07-10 | Scioderm, Inc. | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
| WO2011102532A1 (ja) | 2010-02-16 | 2011-08-25 | 国立大学法人九州大学 | 誘導肝細胞 |
| WO2011110886A1 (en) | 2010-03-09 | 2011-09-15 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| CN102234627B (zh) | 2010-04-30 | 2015-06-03 | 中国科学院广州生物医药与健康研究院 | 一种培养基添加剂及其应用 |
| US9725695B2 (en) | 2010-05-05 | 2017-08-08 | The Regents Of The University Of California | Stem cell defined media for xeno-free and feeder free conditions and uses thereof |
| EP2569424A1 (en) | 2010-05-12 | 2013-03-20 | Cellectis | Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
| US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| EP2392208B1 (en) | 2010-06-07 | 2016-05-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
| WO2011159369A1 (en) | 2010-06-14 | 2011-12-22 | Iowa State University Research Foundation, Inc. | Nuclease activity of tal effector and foki fusion protein |
| CN108531444A (zh) | 2010-08-05 | 2018-09-14 | 威斯康星校友研究基金会 | 用于人多能细胞培养的简化基础培养基 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US20140127814A1 (en) | 2010-08-10 | 2014-05-08 | Srinivasan Chandrasegaran | Generation and use of pluripotent stem cells |
| US9447408B2 (en) | 2010-09-14 | 2016-09-20 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625278A1 (en) | 2010-10-08 | 2013-08-14 | Regents of the University of Minnesota | A method to increase gene targeting frequency |
| WO2012060473A1 (en) | 2010-11-04 | 2012-05-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| AU2012225497A1 (en) | 2011-03-07 | 2013-10-24 | Massachusetts Institute Of Technology | Methods for transfecting cells with nucleic acids |
| WO2012131090A1 (en) | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Method for treatment of xeroderma pigmentosum |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| WO2012174224A2 (en) | 2011-06-17 | 2012-12-20 | Calando Pharmaceuticals, Inc. | Methods for administering nucleic acid-based therapeutics |
| WO2012176015A1 (en) | 2011-06-24 | 2012-12-27 | Leo Pharma A/S | Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate |
| US9862926B2 (en) | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
| WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
| CN103842517A (zh) | 2011-08-03 | 2014-06-04 | 莲花组织修复公司 | 胶原蛋白7及相关方法 |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| EP2766480B1 (en) | 2011-10-11 | 2018-03-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Exon skipping therapy for dystrophic epidermolysis bullosa |
| WO2013078199A2 (en) * | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| EP3260140B1 (en) | 2011-12-05 | 2021-02-03 | Factor Bioscience Inc. | Methods and products for transfecting cells |
| EP2791159A4 (en) * | 2011-12-14 | 2015-10-14 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF |
| ES2923757T3 (es) * | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| AU2012358384A1 (en) | 2011-12-21 | 2014-07-31 | Moderna Therapeutics, Inc. | Methods of increasing the viability or longevity of an organ or organ explant |
| DK3421601T3 (da) | 2011-12-30 | 2020-02-24 | Cellscript Llc | Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| US20150211004A1 (en) * | 2012-04-20 | 2015-07-30 | Agency For Science, Technology And Research | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |
| AU2013251649B2 (en) | 2012-04-24 | 2019-04-04 | Vcell Therapeutics, Inc. | Generating pluripotent cells de novo |
| US10119150B2 (en) | 2012-05-13 | 2018-11-06 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| US10155929B2 (en) | 2012-05-13 | 2018-12-18 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| CN104520424B (zh) | 2012-05-13 | 2019-06-28 | 美国绿阳生物技术及医药公司 | 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞 |
| WO2014015314A1 (en) | 2012-07-19 | 2014-01-23 | University Of Southern California | Recombinant c7 and methods of use |
| CA2890110C (en) | 2012-11-01 | 2023-05-02 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| CN105229144A (zh) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
| US10525075B2 (en) | 2013-02-22 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| WO2014134412A1 (en) | 2013-03-01 | 2014-09-04 | Regents Of The University Of Minnesota | Talen-based gene correction |
| US20160220613A1 (en) | 2013-09-16 | 2016-08-04 | Agency For Science, Technology And Research | Method |
| CN113105559A (zh) | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| US20150167017A1 (en) * | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| KR102415811B1 (ko) * | 2014-01-31 | 2022-07-04 | 팩터 바이오사이언스 인크. | 핵산 제조 및 송달을 위한 방법 및 산물 |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
-
2016
- 2016-02-16 US US15/550,280 patent/US11241505B2/en active Active
- 2016-02-16 CA CA2976376A patent/CA2976376A1/en active Pending
- 2016-02-16 JP JP2017542098A patent/JP7199809B2/ja active Active
- 2016-02-16 EP EP16750065.1A patent/EP3256585A4/en not_active Withdrawn
- 2016-02-16 WO PCT/US2016/018065 patent/WO2016131052A1/en not_active Ceased
- 2016-02-16 EP EP19162770.2A patent/EP3543339A1/en not_active Ceased
- 2016-02-16 AU AU2016218977A patent/AU2016218977C1/en active Active
- 2016-02-16 CN CN201680021235.6A patent/CN109477102A/zh active Pending
- 2016-02-16 EP EP24172111.7A patent/EP4406585A3/en not_active Withdrawn
-
2020
- 2020-02-13 US US16/789,831 patent/US20200261599A1/en not_active Abandoned
-
2021
- 2021-10-01 JP JP2021163064A patent/JP7638844B2/ja active Active
-
2022
- 2022-07-21 AU AU2022206783A patent/AU2022206783A1/en not_active Abandoned
-
2024
- 2024-10-03 JP JP2024174419A patent/JP2025013347A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| GAY, D. et al.,Nature Medicine,2013年 7月,Vol.19, No.7,pp.916-923 |
| KARIKO, K. et al.,Generationg the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified protein-encoding mRNA,Nucleic Acids Research,2011年,Vol.39, No.21, e142,pp.1-10 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4406585A3 (en) | 2024-10-23 |
| US20200261599A1 (en) | 2020-08-20 |
| JP2025013347A (ja) | 2025-01-24 |
| JP2018506542A (ja) | 2018-03-08 |
| US11241505B2 (en) | 2022-02-08 |
| EP3543339A1 (en) | 2019-09-25 |
| AU2016218977B2 (en) | 2022-07-21 |
| EP3256585A1 (en) | 2017-12-20 |
| EP3256585A4 (en) | 2018-08-15 |
| AU2022206783A1 (en) | 2022-08-25 |
| US20180256748A1 (en) | 2018-09-13 |
| CN109477102A (zh) | 2019-03-15 |
| JP7638844B2 (ja) | 2025-03-04 |
| CA2976376A1 (en) | 2016-08-18 |
| WO2016131052A1 (en) | 2016-08-18 |
| JP2022000470A (ja) | 2022-01-04 |
| EP4406585A2 (en) | 2024-07-31 |
| AU2016218977A1 (en) | 2017-08-17 |
| AU2016218977C1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7638844B2 (ja) | 核酸製品及びその投与方法 | |
| JP2023011696A (ja) | 核酸産物およびその投与方法 | |
| HK40013876A (en) | Nucleic acid products and methods of administration thereof | |
| HK1261882A1 (en) | Nucleic acid products and methods of administration thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210305 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210604 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211001 |
|
| C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20211012 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20211012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211007 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220412 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220815 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221018 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20221025 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20221124 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20221124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7199809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |